Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Monica,Mossenta

第一单位： Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.;Department of Life Sciences, University of Trieste, Trieste, Italy.

作者： Monica,Mossenta ^[1] ; Monica,Argenziano ^[2] ; Sara,Capolla ^[3] ; Davide,Busato ^[1] ; Paolo,Durigutto ^[4] ; Alessandro,Mangogna ^[5] ; Maurizio,Polano ^[3] ; Daniele,Sblattero ^[4] ; Roberta,Cavalli ^[2] ; Paolo,Macor ^[4] ; Giuseppe,Toffoli ^[3] ; Michele,Dal Bo ^[3]

作者单位： Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.;Department of Life Sciences, University of Trieste, Trieste, Italy. ^[1] Department of Drug Science and Technology, University of Turin, Turin, Italy. ^[2] Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy. ^[3] Department of Life Sciences, University of Trieste, Trieste, Italy. ^[4] Department of Life Sciences, University of Trieste, Trieste, Italy.;Institute of Pathological Anatomy, Department of Medicine, University of Udine, Udine, Italy. ^[5]

关键词 Hepatocellular carcinoma antibody conjugation, glypican 3 chitosan drug delivery idarubicin nanobubbles